Kura Oncology Inc (KURA)
19.77
-0.29
(-1.45%)
USD |
NASDAQ |
Apr 30, 15:41
Kura Oncology Enterprise Value: 1.113B for April 29, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 29, 2024 | 1.113B |
| April 26, 2024 | 1.081B |
| April 25, 2024 | 1.032B |
| April 24, 2024 | 1.013B |
| April 23, 2024 | 1.011B |
| April 22, 2024 | 970.31M |
| April 19, 2024 | 920.06M |
| April 18, 2024 | 931.48M |
| April 17, 2024 | 955.08M |
| April 16, 2024 | 1.001B |
| April 15, 2024 | 1.033B |
| April 12, 2024 | 1.069B |
| April 11, 2024 | 1.139B |
| April 10, 2024 | 1.101B |
| April 09, 2024 | 1.160B |
| April 08, 2024 | 1.140B |
| April 05, 2024 | 1.136B |
| April 04, 2024 | 1.136B |
| April 03, 2024 | 1.134B |
| April 02, 2024 | 1.148B |
| April 01, 2024 | 1.247B |
| March 28, 2024 | 1.209B |
| March 27, 2024 | 1.197B |
| March 26, 2024 | 1.140B |
| March 25, 2024 | 1.183B |
| Date | Value |
|---|---|
| March 22, 2024 | 1.215B |
| March 21, 2024 | 1.211B |
| March 20, 2024 | 1.256B |
| March 19, 2024 | 1.237B |
| March 18, 2024 | 1.187B |
| March 15, 2024 | 1.286B |
| March 14, 2024 | 1.259B |
| March 13, 2024 | 1.324B |
| March 12, 2024 | 1.284B |
| March 11, 2024 | 1.323B |
| March 08, 2024 | 1.377B |
| March 07, 2024 | 1.280B |
| March 06, 2024 | 1.314B |
| March 05, 2024 | 1.187B |
| March 04, 2024 | 1.208B |
| March 01, 2024 | 1.229B |
| February 29, 2024 | 1.190B |
| February 28, 2024 | 1.213B |
| February 27, 2024 | 1.242B |
| February 26, 2024 | 1.164B |
| February 23, 2024 | 1.127B |
| February 22, 2024 | 1.077B |
| February 21, 2024 | 1.107B |
| February 20, 2024 | 1.129B |
| February 16, 2024 | 1.155B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
63.62M
Minimum
Mar 18 2020
2.430B
Maximum
Dec 11 2020
671.75M
Average
552.97M
Median
Jun 14 2019
Enterprise Value Benchmarks
| Tivic Health Systems Inc | -1.848M |
| AIM ImmunoTech Inc | 8.173M |
| Perspective Therapeutics Inc | 955.03M |
| Protalix BioTherapeutics Inc | 63.35M |
| Armata Pharmaceuticals Inc | 162.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.79M |
| Total Expenses (Quarterly) | 46.76M |
| EPS Diluted (Quarterly) | -0.55 |
| Earnings Yield | -10.52% |